Novel Low-Density Lipoprotein Cholesterol Reduction Therapies for the Secondary Prevention of Cardiovascular Disease

被引:0
作者
Wang, Xing [1 ]
Wen, Dingke [1 ]
Fang, Mei [1 ,2 ]
You, Chao [1 ]
Ma, Lu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, Chengdu 610041, Sichuan, Peoples R China
关键词
monoclonal antibody; low-density lipoprotein; proprotein convertase subtilisin/kexin type 9; secondary prevention; bempedoic acid; BEMPEDOIC ACID; HIGH-RISK; EFFICACY; SAFETY; ALIROCUMAB; INHIBITORS; PCSK9;
D O I
10.31083/j.rcm2410286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To date, optimal agents for low-density lipoprotein cholesterol (LDL-C) reduction in patients with established atherosclerotic cardiovascular disease are still being explored. Thus, we evaluated the efficiency of novel LDL-C-lowering therapies in the secondary prevention of cardiovascular events. Methods: We included randomized clinical trials (RCTs) that explored the effects of different LDL-C lowering agents including alirocumab, evolocumab, and bempedoic acid in adult patients with cardiovascular disease. Several databases were searched from inception through 2022. The safety endpoint includes new-onset diabetes, serious adverse events, and neurocognitive disorders with at least 1 year of follow-up. The efficacy outcomes included composite adverse cardiovascular outcomes, all-cause death, and cardiovascular death. Results: Seven RCTs comprising 53,106 patients were included in this research. Bempedoic acid ranked first in reducing the risk of new-onset diabetes (risk ratio [RR] 0.72, 95% credible interval [CrI] 0.52-0.99) and risk of the composite cardiovascular outcome (RR 0.75, 95% CrI 0.57-0.99). Meta-regression analysis demonstrated that elevated risk of new-onset diabetes was positively correlated with a significant reduction in LDL-C levels (p = 0.03). All treatment agents were associated with a decreased risk of a composite adverse cardiovascular outcome. Conclusions: The present analysis showed that bempedoic acid ranked first in reducing the risk of a composite cardiovascular outcome. In addition, it ranked first in reducing the risk of new-onset diabetes compared with placebo and evolocumab. Our analysis also suggests that the increased risk of new-onset diabetes might be associated with a reduction in LDL-C levels. Besides, the present analysis found that alirocumab ranked first in decreasing all-cause mortality and cardiovascular mortality.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta
    Chen, Guanmin
    Farris, Megan S.
    Cowling, Tara
    Colgan, Stephen M.
    Xiang, Pin
    Pericleous, Louisa
    Rogoza, Raina M.
    Tai, Ming-Hui
    Anderson, Todd
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (07) : 884 - 891
  • [22] Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
    Stein, Evan A.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2009, 38 (01) : 99 - +
  • [23] Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
    Pradhan, Akshyaya
    Bhandari, Monika
    Vishwakarma, Pravesh
    Singh, Abhishek
    Perrone, Marco Alfonso
    Sethi, Rishi
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (05)
  • [24] Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
    Mayr, Manuel
    Gerszten, Robert
    Kiechl, Stefan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (06) : 633 - 635
  • [25] Low-density lipoprotein cholesterol lowering treatment: the current approach
    Crismaru, Irina
    Pantea Stoian, Anca
    Bratu, Ovidiu Gabriel
    Gaman, Mihnea-Alexandru
    Stanescu, Ana Maria Alexandra
    Bacalbasa, Nicolae
    Diaconu, Camelia Cristina
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [26] Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
    Luo, Jie
    Wang, Jin-Kai
    Song, Bao-Liang
    LIFE METABOLISM, 2022, 1 (01): : 25 - 38
  • [27] Association between Lowering Low-Density Lipoprotein Cholesterol with Pravastatin and Primary Prevention of Cardiovascular Disease in Mild to Moderate Hypercholesterolemic Japanese
    Teramoto, Tamio
    Nakaya, Noriaki
    Yokoyama, Shinji
    Ohashi, Yasuo
    Mizuno, Kyoichi
    Nakamura, Haruo
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2010, 17 (08) : 879 - 887
  • [28] Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease
    Wadstrom, Benjamin N.
    Pedersen, Kasper M.
    Wulff, Anders B.
    Nordestgaard, Borge G.
    CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (03) : 96 - 104
  • [29] Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
    Bardolia, Chandni
    Amin, Nishita Shah
    Turgeon, Jacques
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [30] Effectiveness of low-density lipoprotein cholesterol reduction with lipid lowering therapy for secondary prevention amongst older individuals: a nationwide cohort study
    Andersson, Niklas W.
    Corn, Giulia
    Dohlmann, Tine L.
    Melbye, Mads
    Wohlfahrt, Jan
    Lund, Marie
    AGE AND AGEING, 2024, 53 (01)